tbuckley/cabot-search huggingface dataset:
Incidenza e mortalità per malaria in Italia, 1999-2000
Authors: R Romi, D Boccolini, G Majori
Journal: Eurosurveillance (2001)

Nel periodo 1999-2000, sono stati notificati dall'Istituto Superiore di Sanita un totale di 2060 casi di malaria. La maggior parte dei pazienti non aveva ricevuto alcuna profilassi oppure era stata curata inappropriatamente. Il 93% aveva contratto l'infezione in paesi malarici africani, il 4% in paesi asiatici, il 3% in America Latina. Per l'84% dei casi si trattava di P. falciparum, seguito da P. vivax (8%), P. ovale (5%) e P. malariae (2%). I decessi corrispondevano a un tasso annuale di fatalita dello 0,3% nel 1999 e dello 0,5% nel 2000. In generale, i casi di malaria importati riflettono il numero di viaggiatori italiani che sottostimano il rischio di infezione nei paesi malarici dell'Asia e dell'America Latina e di residenti in Italia di origine africana che fanno visita ai parenti nel loro paese di origine.
Authors’ reply: An ongoing large outbreak of measles in Merseyside, England, January to June 2012
Authors: R Vivancos, A Keenan
Journal: Eurosurveillance (2012)

Preview this article: Authors' reply: An ongoing large outbreak of measles in Merseyside, England, January to June 2012, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/17/31/art20234-en-1.gif
From nuclear submarines to graduate medical education: applying David Marquet’s intent-based leadership model
Authors: Camilo Fernandez-Salvador, Rebecca Oney, Sungjin A. Song, Macario Camacho
Journal: Military Medical Research (2017)

L. David Marquet, a decorated Navy Captain, transformed an underperforming submarine crew by empowering his subordinates to be leaders and reach their full potential. He called this intent-based leadership (IBL). What would happen if Marquet's model were implemented in Graduate Medical Education (GME)? In this letter to the editor, we summarize the potential of the IBL model in graduate medical education as opposed to the traditional leader-follower method. IBL harnesses human productivity toward the shared goals of GME, which are patient care and trainee learning. This shift in mindset could lead both teachers and trainees to focus more on the real reason that we undertake GME and change behaviors for the better. We suggest that IBL can and should be adopted in GME and propose that both patients and providers will benefit from this action.
GW28-e0446 Traditional Tibetan medicine Corydalis hendersonii exerts anti-myocardial ischemia effect by attenuating inflammation and fibrosis in acute myocardial infarction mice
Authors: Feng Zhao, Ruifeng Bai, Xiao Feng, Hexinge Zhang, Chun Li, Pengfei Tu, Xingyun Chai
Journal: Journal of the American College of Cardiology (2017)
Nitrogen dioxide exposure in school classrooms of inner-city children with asthma
Authors: Jonathan M. Gaffin, Marissa Hauptman, Carter R. Petty, William J. Sheehan, Peggy S. Lai, Jack M. Wolfson, Diane R. Gold, Brent A. Coull, Petros Koutrakis, Wanda Phipatanakul
Journal: Journal of Allergy and Clinical Immunology (2017)
Validation of a Metastatic Assay using biopsies to improve risk stratification in patients with prostate cancer treated with radical radiation therapy
Authors: S. Jain, C.A. Lyons, S.M. Walker, S. McQuaid, S.O. Hynes, D.M. Mitchell, B. Pang, G.E. Logan, A.M. McCavigan, D. O’Rourke, D.G. McArt, S.S. McDade, I.G. Mills, K.M. Prise, L.A. Knight, C.J. Steele, P.W. Medlow, V. Berge, B. Katz, D.A. Loblaw, D.P. Harkin, J.A. James, J.M. O'sullivan, R.D. Kennedy, D.J. Waugh
Journal: Annals of Oncology (2017)

Radiotherapy is an effective treatment of intermediate/high-risk locally advanced prostate cancer, however, >30% of patients relapse within 5 years. Clinicopathological parameters currently fail to identify patients prone to systemic relapse and those whom treatment intensification may be beneficial. The purpose of this study was to independently validate the performance of a 70-gene Metastatic Assay in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy.A bridging cohort of prostate cancer diagnostic biopsy specimens was profiled to enable optimization of the Metastatic Assay threshold before further independent clinical validation in a cohort of diagnostic biopsies from patients treated with radical radiotherapy and androgen deprivation therapy. Multivariable Cox proportional hazard regression analysis was used to assess assay performance in predicting biochemical failure-free survival (BFFS) and metastasis-free survival (MFS).Gene expression analysis was carried out in 248 patients from the independent validation cohort and the Metastatic Assay applied. Ten-year MFS was 72% for Metastatic Assay positive patients and 94% for Metastatic Assay negative patients [HR = 3.21 (1.35-7.67); P = 0.003]. On multivariable analysis the Metastatic Assay remained predictive for development of distant metastases [HR = 2.71 (1.11-6.63); P = 0.030]. The assay retained independent prognostic performance for MFS when assessed with the Cancer of the Prostate Assessment Score (CAPRA) [HR = 3.23 (1.22-8.59); P = 0.019] whilst CAPRA itself was not significant [HR = 1.88, (0.52-6.77); P = 0.332]. A high concordance [100% (61.5-100)] for the assay result was noted between two separate foci taken from 11 tumours, whilst Gleason score had low concordance.The Metastatic Assay demonstrated significant prognostic performance in patients treated with radical radiotherapy both alone and independent of standard clinical and pathological variables. The Metastatic Assay could have clinical utility when deciding upon treatment intensification in high-risk patients. Genomic and clinical data are available as a public resource.
GW28-e0907 Insulin reverses MCP-1 suppressed cholesterol efflux to HDL3/ApoA1 through up-regulation of ABCA1, ABCG1 and SR-BI in differentiated 3T3-L1 adipocytes
Authors: Runlu Sun, Canxia Huang, Jieyu Jiang, Jinlan Bao, Yuling Zhang
Journal: Journal of the American College of Cardiology (2017)
A growth-accommodating implant for paediatric applications
Authors: Eric N. Feins, Yuhan Lee, Eoin D. O’Cearbhaill, Nikolay V. Vasilyev, Shogo Shimada, Ingeborg Friehs, Douglas Perrin, Peter E. Hammer, Haruo Yamauchi, Gerald Marx, Andrew Gosline, Veaceslav Arabagi, Jeffrey M. Karp, Pedro J. del Nido
Journal: Nature Biomedical Engineering (2017)
Calcium Oxalate Crystals in Ethylene Glycol Toxicity
Authors: Mohamad Hanouneh, Teresa K Chen
Journal: New England Journal of Medicine (2017)

An 80-year-old man presented to the emergency department after a fall at home. Serum studies demonstrated an anion and osmolal gap. Examination of the urine sediment showed calcium oxalate monohydrate crystals, suggestive of ethylene glycol toxicity.
Christopher Paul Lindsay Freeman
Authors: Tom Brown, Derek Chiswick, James Hendry
Journal: BMJ (2017)

Christopher Paul Lindsay Freeman (“Chris”) was born and brought up in York and after qualifying trained as a psychiatrist in Edinburgh. During his training he won the coveted Gaskell medal of the Royal College of Psychiatrists. He became one of the foremost psychiatrists of his generation, making important contributions across numerous areas in Scotland and beyond. He was an innovator, not scared to challenge orthodoxy, imbued with huge drive and energy, which allowed him to develop much needed new services.

He was appointed to a senior lecturer post at Edinburgh University in 1980 and to an honorary consultant post at the Royal Edinburgh Hospital. Although initially a general psychiatrist, he soon developed a special interest in eating disorders, and in 1984 he moved to a consultant psychotherapy post to pursue this. …
Efficacy and tolerability of chronomodulated FOLFIRINOX (chronoIFLO) as 1st or 2nd line treatment in patients (pts) with metastatic colorectal cancer (MCC): Final results from an international trial (EORTC 05011)
Authors: C. Garufi, F. Levi, A. Karaboué, A. Torsello, C. Focan, P. Chollet, P. INNOMINATO
Journal: Annals of Oncology (2017)
Haploinsufficiency of NADPH Oxidase Subunit Neutrophil Cytosolic Factor 2 Is Sufficient to Accelerate Full‐Blown Lupus in NZM 2328 Mice
Authors: Chaim O. Jacob, Ning Yu, Dae‐Goon Yoo, Lizet J. Perez‐Zapata, Emilia Alina Barbu, Mariana J. Kaplan, Monica Purmalek, Jeanette T. Pingel, Rachel A. Idol, Mary C. Dinauer
Journal: Arthritis & Rheumatology (2017)

Objective We have previously established that the gene for neutrophil cytosolic factor 2 (NCF‐2) predisposes to lupus, and we have identified lupus patients with point mutations that are predicted to cause reduced NADPH oxidase activity. We undertook this study to investigate the relationship between reduced leukocyte NADPH oxidase activity and immune dysregulation associated with systemic lupus erythematosus (SLE). Methods We generated NCF‐2–null mice, in which NADPH oxidase activity is absent, on the nonautoimmune C57BL/6 (B6) mouse background and on the NZM 2328 mouse background, a polygenic model in which mice spontaneously develop lupus. Clinical disease, serology, and immunopathology were evaluated. Results NCF‐2–null mice on the B6 background were susceptible to Aspergillus fumigatus pneumonia characteristic of chronic granulomatous disease, but did not develop systemic lupus disease. In contrast, NCF‐2–null and even NCF‐2–haploinsufficient mice on the NZM 2328 background developed accelerated full‐blown lupus with significantly accelerated lupus kidney disease. This was characterized by more rapid development of hyperactive B cell and T cell immune compartments, increased expression of type I interferon–responsive genes, and generation of neutrophil extracellular traps, which were observed even in the absence of NADPH oxidase activity. Conclusion Just as patients with chronic granulomatous disease who lack NADPH oxidase rarely develop SLE, NCF‐2–null mice on a nonautoimmune background were susceptible to a chronic granulomatous disease–like opportunistic infection but did not develop lupus. In contrast, on a lupus‐prone background, even haploinsufficiency of NCF‐2 accelerated the development of full‐blown lupus disease. This establishes an interaction between reduced oxidase activity and other lupus‐predisposing genes, paralleling human SLE–associated variants predicted to have only reduced NADPH oxidase activity.
Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group
Authors: Amy K. Erbe, Wei Wang, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonça, Yiqiang Song, Dustin Hess, Patrick K. Reville, Wendy B. London, Arlene Naranjo, Jacquelyn A. Hank, Mitchell B. Diccianni, Ralph A. Reisfeld, Stephen D. Gillies, Katherine K. Matthay, Susan L. Cohn, Michael D. Hogarty, John M. Maris, Julie R. Park, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu, Paul M. Sondel
Journal: Clinical Cancer Research (2017)

Purpose: In 2010, a Children's Oncology Group (COG) phase III randomized trial for patients with high-risk neuroblastoma (ANBL0032) demonstrated improved event-free survival (EFS) and overall survival (OS) following treatment with an immunotherapy regimen of dinutuximab, GM-CSF, IL2, and isotretinoin compared with treatment with isotretinoin alone. Dinutuximab, a chimeric anti-GD2 monoclonal antibody, acts in part via natural killer (NK) cells. Killer immunoglobulin-like receptors (KIR) on NK cells and their interactions with KIR-ligands can influence NK cell function. We investigated whether KIR/KIR-ligand genotypes were associated with EFS or OS in this trial.Experimental Design: We genotyped patients from COG study ANBL0032 and evaluated the effect of KIR/KIR-ligand genotypes on clinical outcomes. Cox regression models and log-rank tests were used to evaluate associations of EFS and OS with KIR/KIR-ligand genotypes.Results: In this trial, patients with the "all KIR-ligands present" genotype as well as patients with inhibitory KIR2DL2 with its ligand (HLA-C1) together with inhibitory KIR3DL1 with its ligand (HLA-Bw4) were associated with improved outcome if they received immunotherapy. In contrast, for patients with the complementary KIR/KIR-ligand genotypes, clinical outcome was not significantly different for patients who received immunotherapy versus those receiving isotretinoin alone.Conclusions: These data show that administration of immunotherapy is associated with improved outcome for neuroblastoma patients with certain KIR/KIR-ligand genotypes, although this was not seen for patients with other KIR/KIR-ligand genotypes. Further investigation of KIR/KIR-ligand genotypes may clarify their role in cancer immunotherapy and may enable KIR/KIR-ligand genotyping to be used prospectively for identifying patients likely to benefit from certain cancer immunotherapy regimens. Clin Cancer Res; 24(1); 189-96. ©2017 AACRSee related commentary by Cheung and Hsu, p. 3.
Exosomal-miRNA profiles as diagnostic biomarkers in cervical cancer.
Authors: Hirotaka Nishi, Yuzo Nagamitsu, Toru Sasaki, Yotaro Takaesu, Fumitoshi Terauchi, Keiichi Isaka
Journal: Journal of Clinical Oncology (2012)

10557 Background: MicroRNA (miRNA) expression is altered in cancer cells and associated with the development and progression of various types of cancer. miRNA could serve as diagnostic or prognostic biomarker for cancer patients. Our study was designed to analyze circulating exosomal-miRNA in patients with cervical cancer. Methods: Total RNA was extracted from serum in healthy women and patients with cervical intraepithelial neoplasia (CIN) and cervical cancer. We first explored miRNA expression profiles using miRCURY LNA microRNA Array (Exiqon) in each six malignant and healthy serum samples. miRNAs with significant differences in expression were validated in larger sample sets by a quantitative real-time RT-PCR using TaqMan gene expression assays (Applied Biosystems). Results: Six of 1223 miRNAs compared in serum samples from cervical cancer and normal control were found to have a &gt;3.0-fold change with a P value &lt;0.01 using miRCURY LNA microRNA Array. In a validation set (n=101), expression of 3 of the 6 miRNAs, miR-483-5p, miR-1246 and miR-1275, was significantly different between the cervical cancer (n=40) and control (n=20) samples. We also found that the median levels of these miRNAs were significantly higher in patients with cervical cancer (n=40) than those in CIN (n=41). Circulating miRNAs were not correlated with clinical-pathological parameters except for miR-1246. Compared to patients with squamous cell carcinoma, the miR-1246 level was significantly higher in those with adenocarcinoma. Whereas, receiver-operator characteristic (ROC) curve analyses suggest that these serum miRNAs may be useful markers for discriminating patients with cervical cancer from healthy controls. Conclusions: Expression of circulating miR-483-5p, miR-1246 and miR-1275 is significantly higher in the blood of cervical cancer patients compared to controls and may potentially serve as a useful biomarker for cervical cancer diagnosis. Especially, miR-1246 may be a candidate for early detection of cervical adenocarcinoma. Larger-scaled studies are warranted to fully explore the role of circulating exosomal-miRNAs in cervical cancer.
Overall survival (OS) by platelet count at baseline in patients with hepatocellular carcinoma (HCC) treated with sorafenib (SOR) in the SHARP and AP trials and regorafenib (REG) in the RESORCE trial
Authors: G. Meinhardt, Y. De Sanctis, M-A. LeBerre, K. Nakajima
Journal: Annals of Oncology (2017)
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
Authors: Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, Petronella G M Peer, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Hiltje De Graaf, Aafke H Honkoop, Frans L G Erdkamp, Franchette W P J van den Berkmortel, Maaike de Boer, Wilfred K de Roos, Sabine C Linn, Alexander L T Imholz, Caroline M Seynaeve, J.J.E.M. Kitzen, L.J.A. Strobbe, E.A. Kouwenhoven, T. van Dalen, A.J. van Overbeeke, J.K.S. Nuytinck, I.E. Arntz, R.J.B. Blaisse, H.B.A.C. Stockmann, P.H.A. Nijhuis, G.J. Veldhuis, W.J.B. Mastboom, J.M.G.H. van Riel, J.H. van Dam, M.O. den Boer, M.J. Agterof, M.A.J. de Roos, R.M.H. Roumen, J.J.M. van der Hoeven, A. Beeker, R. Koelemij, A. van Bochove, G.S. Madretsma, E.J.M. Siemerink, O.R. Guicherit, A.H. Vos, G.A.P. Nieuwenhuijzen, D.F.S. Kehrer, F.A.A. Valster, B.C. Tanis, T. van Voorthuizen, A.M.T. van der Velden, R.A. Hellingman, R. Vree, Q. van Rossum-Schornagel, J.M. Meerum Terwogt, W.G. van Leeuwen-Breuk, J.G. Haasjes, M.A. Davidis-van Schoonhoven, E.J.C. Vriens, M. Jagers, E.W. Muller, P.P.J.B.M. Schiphorst, C.J. van Groeningen, M.A. van Dijk, E. Janssens- van Vliet, E.E.M. Schepers, J.W.S. Merkus, N.G.J. van Diemen, R.C. van Doorn, K. Bosscha, R. den Toom, P.C. van der Velden, C.T.A.M. van Rossum, H.M. Oosterkamp, R. van Hillegersberg, B. Jas, E.E.M. Weernink, J.M.A. Ketel, J.J. Jansen, J.K. Maring, M.J.P.M. Govaert, Y.J.L. Kamm, M.M. Vleugel, S. Hovenga, J. de Boer, H. Potthoff, D.W. Sommeijer, E.J. van Dulken
Journal: The Lancet Oncology (2017)
Abstract 13728: Poor Trunk Flexibility is Associated With Greater Progression of Age-related Arterial Stiffening: A 5-year Longitudinal Study
Authors: Yuko Gando, Kenta Yamamoto, Haruka Murakami, Ryoko Kawakami, Harumi Ohno, Susumu S Sawada, Nobuyuki Miyatake, Motohiko Miyachi
Journal: Circulation (2016)

Introduction: Low level of physical fitness, especially cardiorespiratory fitness, appear to accelerate age-related aortic stiffening. Whereas, some studies have reported that flexibility, is one of the components of physical fitness, is also associated with arterial stiffening independent of cardiorespiratory fitness in cross sectional studies. However, no longitudinal study has determined whether poor trunk flexibility might accelerate the progression of age-related aortic stiffening. Hypothesis: Poor trunk flexibility is associated with greater progression of age-related aortic stiffening in apparently healthy adults. Methods: We examined trunk flexibility and aortic stiffness progression in a 5-year follow-up study of 361 healthy men and women aged 27-73 years. Trunk flexibility was measured by a sit-and-reach test. Aortic stiffness was assessed using carotid-femoral pulse wave velocity (cfPWV) at baseline and after 5 years. To assess the effects of flexibility level on the progression of aortic stiffening, the participants were categorized into tertiles (Low, Middle, High) based on their sit-and-reach test values at baseline. ANCOVA was used to analyze the association of the annual rate of cfPWV (cm/ sec/ year) [annual ΔcfPWV = (follow-up cfPWV- baseline cfPWV) / follow-up years] across flexibility levels. Baseline age, BMI, cfPWV, brachial systolic blood pressure, cardiorespiratory fitness and sex were entered as covariates for adjustment. Results: The annual ΔcfPWV was significantly greater in the low (poor) flexibility group (10.95±2.49 cm/sec/year) than in the high flexibility group (2.19±2.41 cm/sec/year) (P=0.041). An inverse relationship was observed between flexibility level and the annual ΔcfPWV (P for trend = 0.042). The multiple regression analysis revealed that baseline sit and reach (β = -0.125), age (β = 0.197), cfPWV (β = - 0.432), cardiorespiratory fitness (β = -0.144), and sex (β = - 0.174) were independent correlates of ΔcfPWV. These data indicate that flexibility is associated with aortic stiffness, independent of other factors already known to be related to arterial stiffness. Conclusions: Poor flexibility is associated with greater progression of age-related aortic stiffening.
Trastuzumab and paclitaxel in patients (pts) with EGFR mutated non-small-cell lung cancer (NSCLC) that express HER2 after progression on EGFR TKI treatment.
Authors: Joop De Langen, Justine Leonie Kuiper, Erik Thunnissen, Sayed MS Hashemi, Kim Monkhorst, Egbert F. Smit
Journal: Journal of Clinical Oncology (2017)

9042 Background: HER2 expression as well as amplification has been well recognized in tumor biopsies of pts with an EGFR mutation who developed EGFR TKI resistance. It is unknown whether HER2 targeting in this setting can result in tumor responses. Methods: Single arm open label phase II study to study the safety and efficacy of paclitaxel-trastuzumab treatment in pts with a sensitizing EGFR mutation who show tumor membrane HER2 expression in a tumor biopsy (immunohistochemistry (IHC) ≥1) after progression on EGFR TKI treatment. Paclitaxel (60 mg/m2) and trastuzumab (first dose 4 mg/kg, thereafter 2 mg/kg) were dosed weekly until disease progression or unacceptable toxicity. Primary end-point was tumor response according to RECIST. Sample size of 20 pts was calculated to evaluate the primary objective of ≥30% objective response rate. The study was deemed positive when ≥7 pts would show a partial or complete response. Results: 21 pts were enrolled from 08-2012 to 02-2017. 7 pts were exon 21 L858R positive and 14 exon 19 del. Last TKI was erlotinib (n = 6), gefitinib (n = 4), rociletinib (n = 3) or osimertinib (n = 8). Median HER2 IHC was 2+ (range 1-3). 17 pts were evaluable for response assessment, while 4 pts are awaiting their first response scan. The primary end-point was met with 7/17 pts (41%) showing a partial response. 2 pts showed stable disease, 7 progressive disease and 1 pt had clinical progression before CT response evaluation. Median duration of response was 9 (range 6-18) months with one ongoing responder. 3 pts experienced grade ≥3 toxicity, including fatigue, neuropathy and neutropenia. Upon progression on study treatment, all responding pts were rebiopsied. 4/6 samples were negative for HER2 (IHC), suggesting that the combination effectively targeted HER2 positive tumor cells. Conclusions: The study met its primary end-point. Paclitaxel-trastuzumab induces durable objective tumor responses in EGFR TKI pretreated pts with an activating EGFR mutation and HER2 bypass track activation. The treatment was well tolerated. Post-progression tumor biopsies showed absence of HER2 staining in the majority of pts, suggesting effective HER2 targeting. Clinical trial information: NCT02226757.
Epidemiology of malignant cutaneous granular cell tumors: A US population-based cohort analysis using the Surveillance, Epidemiology, and End Results (SEER) database
Authors: Fatima N. Mirza, Charles T. Tuggle, Cheryl K. Zogg, Humza N. Mirza, Deepak Narayan
Journal: Journal of the American Academy of Dermatology (2017)
Expression of stem cell and mesenchymal markers in circulating tumor cells is associated with poor prognosis of early breast cancer patients
Authors: A. Nagel, A. Markiewicz, J. Szade, H. Majewska, J. Skokowski, B. Seroczynska, M. Welnicka-Jaskiewicz, A. Zaczek
Journal: Annals of Oncology (2017)
Primary results from the phase III ALUR study of alectinib versus chemotherapy in previously treated ALK+ non-small-cell lung cancer (NSCLC)
Authors: S. Novello, J. Mazieres, I-J. Oh, J. de Castro, M.R. Migliorino, A. Helland, R. Dziadziuszko, F. Griesinger, A. Kotb, A. Zeiter, A. Cardona, B. Balas, H. Johannsdottir, A. Das-Gupta, J. Wolf
Journal: Annals of Oncology (2017)